Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Earnings Preview | Novartis (NVS.US) faces a critical test with a 16x PE ratio, as key data for three blockbuster new drugs in the second half of the year will be the “touchstone” for valuation

Earnings Preview | Novartis (NVS.US) faces a critical test with a 16x PE ratio, as key data for three blockbuster new drugs in the second half of the year will be the “touchstone” for valuation

智通财经智通财经2026/07/20 07:06
Show original
Smart Finance APP has noticed that, while investors in Novartis (NVS.US) are paying attention to the quarterly results released on Tuesday, they are even more focused on the upcoming results of three major drug trials set to be announced in the second half of this year. These results are seen as critical evidence justifying the premium valuation of the Swiss pharmaceutical company.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Federal Reserve Governor Cook: AI productivity dividends are difficult to curb inflation, and the Federal Reserve may need to further tighten policies

Federal Reserve Governor Lisa Cook stated on Monday that future productivity gains driven by artificial intelligence may not be sufficient to offset recent price pressures and warned that this trend could increase overall economic inflation.

智通财经•2026/09/28 22:46